Improvement of RBD-FC Immunogenicity by Using Alum-Sodium Alginate Adjuvant Against SARS-COV-2

被引:1
|
作者
Dehghan, Mahboobeh [1 ]
Askari, Hossein [1 ]
Tohidfar, Masoud [1 ]
Siadat, Seyed Omid Ranaei [2 ]
Fatemi, Fataneh [2 ]
机构
[1] Shahid Beheshti Univ, Fac Life Sci & Biotechnol, Dept Cellular & Mol Biol, Tehran, Iran
[2] Shahid Beheshti Univ, Prot Res Ctr, Tehran, Iran
关键词
aluminum hydroxide; cytokine; immunogenicity; RBD-FC; SARS-CoV-2; sodium alginate; vaccine; RECEPTOR-BINDING DOMAIN; SPIKE PROTEIN; VACCINE ADJUVANTS; DELIVERY-SYSTEMS; CHITOSAN; CORONAVIRUSES; ANTIBODIES;
D O I
10.1111/irv.70018
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
BackgroundAdjuvants use several mechanisms to boost immunogenicity and to modulate immune response. The strength of adsorption of antigen by adjuvants can be a determinant factor for significant improvement of immunopotentiation.MethodsWe expressed recombinant RBD-FC in PichiaPink Strain 4 and examined the vaccination of mice by vaccine formulation with different adjuvants (sodium alginate and aluminum hydroxide, alone and together).ResultsSodium alginate significantly increased the immunogenicity and stability of RBD-FC antigen, so RBD-FC formulated with combined alginate and alum (AlSa) and sodium alginate alone showed higher antibody titer and stability. Immunogenicity of RBD-FC:AlSa was determined by serological assays including direct enzyme-linked immunosorbent assay (ELISA) and surrogate virus neutralization test (sVNT). High levels of IgGs and neutralizing antibodies were measured in serum of mice immunized with the RBD-FC:AlSa formulation. On the other hand, cytokines IL-10 and INF-gamma were severely accumulated in response to RBD-FC:AlSa, and after 10 days, their accumulation was significantly declined, whereas IL-4 showed the highest and the lowest accumulation in response to alum and alginate, respectively.ConclusionsOur data may suggest that combination of alum and sodium alginate has a better compatibility with RBD-FC in vaccine formulation.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice
    Shihui Sun
    Lei He
    Zhongpeng Zhao
    Hongjing Gu
    Xin Fang
    Tiecheng Wang
    Xiaolan Yang
    Shaolong Chen
    Yongqiang Deng
    Jiangfan Li
    Jian Zhao
    Liang Li
    Xinwang Li
    Peng He
    Ge Li
    Hao Li
    Yuee Zhao
    Chunrun Gao
    Xiaoling Lang
    Xin Wang
    Guoqiang Fei
    Yan Li
    Shusheng Geng
    Yuwei Gao
    Wenjin Wei
    Zhongyu Hu
    Gencheng Han
    Yansong Sun
    Cellular & Molecular Immunology, 2021, 18 : 1070 - 1073
  • [2] Preclinical assessment of a recombinant RBD-Fc fusion protein as SARS-CoV-2 candidate vaccine
    Dashti, Navid
    Golsaz-Shirazi, Forough
    Soltanghoraee, Haleh
    Zarnani, Amir-Hassan
    Mohammadi, Mehdi
    Imani, Danyal
    Jeddi-Tehrani, Mahmood
    Amiri, Mohammad Mehdi
    Shokri, Fazel
    EUROPEAN JOURNAL OF MICROBIOLOGY AND IMMUNOLOGY, 2024, 14 (03): : 228 - 242
  • [3] Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice
    Sun, Shihui
    He, Lei
    Zhao, Zhongpeng
    Gu, Hongjing
    Fang, Xin
    Wang, Tiecheng
    Yang, Xiaolan
    Chen, Shaolong
    Deng, Yongqiang
    Li, Jiangfan
    Zhao, Jian
    Li, Liang
    Li, Xinwang
    He, Peng
    Li, Ge
    Li, Hao
    Zhao, Yuee
    Gao, Chunrun
    Lang, Xiaoling
    Wang, Xin
    Fei, Guoqiang
    Li, Yan
    Geng, Shusheng
    Gao, Yuwei
    Wei, Wenjin
    Hu, Zhongyu
    Han, Gencheng
    Sun, Yansong
    CELLULAR & MOLECULAR IMMUNOLOGY, 2021, 18 (04) : 1070 - 1073
  • [4] An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants
    Luo, Deyan
    Yang, Xiaolan
    Li, Tao
    Ning, Nianzhi
    Jin, Song
    Shi, Zhuangzhuang
    Gu, Hongjing
    Li, Deyu
    Gao, Yuwei
    Wang, Hui
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2022, 7 (01)
  • [5] An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants
    Deyan Luo
    Xiaolan Yang
    Tao Li
    Nianzhi Ning
    Song Jin
    Zhuangzhuang Shi
    Hongjing Gu
    Deyu Li
    Yuwei Gao
    Hui Wang
    Signal Transduction and Targeted Therapy, 7
  • [6] CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2
    Laotee, Sedthawut
    Duangkaew, Methawee
    Jivapetthai, Araya
    Tharakhet, Kittipan
    Kaewpang, Papatsara
    Prompetchara, Eakachai
    Phumiamorn, Supaporn
    Sapsutthipas, Sompong
    Trisiriwanich, Sakalin
    Somsaard, Thitiporn
    Roytrakul, Sittiruk
    Duangkhae, Parichat
    Ongpipattanakul, Boonsri
    Limpikirati, Patanachai
    Pornputtapong, Natapol
    Arunmanee, Wanatchaporn
    PLOS ONE, 2023, 18 (07):
  • [7] Development of nanoparticle vaccines utilizing designed Fc-binding homo-oligomers and RBD-Fc of SARS-CoV-2
    Liang, Yucai
    Xiao, Weiling
    Peng, Yuan
    Zhang, Shengshuo
    Dong, Jinhua
    Zhao, Jun
    Wang, Yuhui
    Zhang, Mengtao
    Liu, Zhijun
    Yu, Bowen
    ANTIVIRAL RESEARCH, 2024, 227
  • [8] Immunogenicity and safety of a RBD vaccine against SARS-CoV-2 in a murine model
    Diaz, Andres
    Serrano-Coll, Hector
    Botero, Yesica
    Calderon, Alfonso
    Arteta-Cueto, Ariel
    Gastelbondo, Bertha
    Guzman, Camilo
    Rivero, Ricardo
    Martinez, Caty
    Marquez, Tania
    Arrieta, German
    Mattar, Salim
    TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2022, 49
  • [9] The immunogenicity of Alum plus CpG adjuvant SARS-CoV-2 inactivated vaccine in mice
    Yang, Jie
    Li, Boran
    Yang, Dongsheng
    Wu, Jie
    Yang, Anna
    Wang, Wenhui
    Lin, Fengjie
    Wan, Xin
    Li, YuWei
    Chen, Zhuo
    Lv, Shiyun
    Pang, Deqin
    Liao, Wenbo
    Meng, Shengli
    Lu, Jia
    Guo, Jing
    Wang, Zejun
    Shen, Shuo
    VACCINE, 2023, 41 (41) : 6064 - 6071
  • [10] Comparison of Immunogenicity of Alum and MF59-Like Adjuvant Inactivated SARS-CoV-2 Vaccines Against SARS-CoV-2 Variants in Elderly Mice
    Bai, Shuang
    Kang, Yanli
    Chen, Weixin
    Xie, Hui
    Zhang, Lichi
    Lv, Min
    Wang, Jian
    Wu, Jiang
    Zhao, Wei
    VIRAL IMMUNOLOGY, 2023, 36 (08) : 526 - 533